Genocea Biosciences Stock Price, News & Analysis (NASDAQ:GNCA)

$1.15 -0.02 (-1.71 %)
(As of 11/20/2017 06:43 AM ET)
Previous Close$1.17
Today's Range$1.14 - $1.21
52-Week Range$1.03 - $7.29
Volume375,300 shs
Average Volume583,324 shs
Market Capitalization$33.01 million
P/E RatioN/A
Dividend YieldN/A
Beta1.93

About Genocea Biosciences (NASDAQ:GNCA)

Genocea Biosciences logoGenocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:GNCA
  • CUSIP: N/A
  • Web: www.genocea.com
Debt:
  • Debt-to-Equity Ratio: 2.51%
  • Current Ratio: 1.55%
  • Quick Ratio: 1.55%
Sales & Book Value:
  • Annual Sales: $230,000.00
  • Price / Sales: 143.50
  • Book Value: $1.60 per share
  • Price / Book: 0.72
Profitability:
  • Trailing EPS: ($2.17)
  • Net Income: ($49,570,000.00)
  • Return on Equity: -190.18%
  • Return on Assets: -110.64%
Misc:
  • Employees: 98
  • Outstanding Shares: 28,700,000
 

Frequently Asked Questions for Genocea Biosciences (NASDAQ:GNCA)

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) announced its earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.08. During the same quarter in the prior year, the company posted ($0.45) earnings per share. View Genocea Biosciences' Earnings History.

When will Genocea Biosciences make its next earnings announcement?

Genocea Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, February, 14th 2018. View Earnings Estimates for Genocea Biosciences.

Where is Genocea Biosciences' stock going? Where will Genocea Biosciences' stock price be in 2017?

5 equities research analysts have issued 1-year target prices for Genocea Biosciences' shares. Their predictions range from $2.50 to $12.00. On average, they anticipate Genocea Biosciences' stock price to reach $7.38 in the next year. View Analyst Ratings for Genocea Biosciences.

What are Wall Street analysts saying about Genocea Biosciences stock?

Here are some recent quotes from research analysts about Genocea Biosciences stock:

  • 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (10/16/2017)
  • 2. Needham & Company LLC analysts commented, "Genocea announced positive results from its Phase 2b trial of GEN-003 in Herpes Simplex Type 2 (HSV2) in early Jan 2017. Given financial constraints, however, mgmt now plans to seek a collaborator prior to initiation of Phase 3 development. We believe this creates meaningful uncertainty for GEN-003 development timelines as well as the stock. Mgmt previously announced a shift in strategic focus from infectious disease to immuno-oncology. However, initial candidate from latter program is not expected to reach clinical development until YE17. We are downgrading to HOLD based on uncertainty around GEN-003 and lack of near-term milestones w/ immuno-oncology program. ATLAS platform holds substantial value and we believe stock remains attractive for long-term investors w/ horizon beyond 2017." (2/17/2017)

Who are some of Genocea Biosciences' key competitors?

Who are Genocea Biosciences' key executives?

Genocea Biosciences' management team includes the folowing people:

  • Katrine S. Bosley, Chairman of the Board (Age 49)
  • William D. Clark, President, Chief Executive Officer, Director (Age 55)
  • Jonathan M. Poole, Chief Financial Officer (Age 42)
  • John E. Bishop Ph.D., Executive Vice President - Pharmaceutical Sciences (Age 54)
  • Jessica Baker Flechtner Ph.D., Chief Scientific Officer (Age 44)
  • Seth V. Hetherington M.D., Chief Medical Officer (Age 63)
  • Eric S. Hoffman Ph.D., Chief Business Officer (Age 47)
  • Ronald Harold Wilfred Cooper, Director (Age 54)
  • George Siber M.D., Director
  • Kenneth M. Bate, Independent Director (Age 66)

Who owns Genocea Biosciences stock?

Genocea Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Northpointe Capital LLC (2.88%). Company insiders that own Genocea Biosciences stock include Eric S Hoffman, Jonathan Poole and William D Clark. View Institutional Ownership Trends for Genocea Biosciences.

Who sold Genocea Biosciences stock? Who is selling Genocea Biosciences stock?

Genocea Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Northpointe Capital LLC. View Insider Buying and Selling for Genocea Biosciences.

How do I buy Genocea Biosciences stock?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genocea Biosciences' stock price today?

One share of Genocea Biosciences stock can currently be purchased for approximately $1.15.

How big of a company is Genocea Biosciences?

Genocea Biosciences has a market capitalization of $33.01 million and generates $230,000.00 in revenue each year. The biotechnology company earns ($49,570,000.00) in net income (profit) each year or ($2.17) on an earnings per share basis. Genocea Biosciences employs 98 workers across the globe.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]


MarketBeat Community Rating for Genocea Biosciences (NASDAQ GNCA)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  266
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Genocea Biosciences (NASDAQ:GNCA)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $7.38 (541.30% upside)

Consensus Price Target History for Genocea Biosciences (NASDAQ:GNCA)

Price Target History for Genocea Biosciences (NASDAQ:GNCA)

Analysts' Ratings History for Genocea Biosciences (NASDAQ:GNCA)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017Piper Jaffray CompaniesReiterated RatingOverweight$5.00N/AView Rating Details
9/26/2017Needham & Company LLCDowngradeBuy -> HoldHighView Rating Details
9/26/2017Cowen and CompanyReiterated RatingBuy$10.00HighView Rating Details
9/25/2017Stifel NicolausDowngradeBuy -> Hold$15.00 -> $2.50HighView Rating Details
1/23/2017FBR & CoReiterated RatingOutperformN/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Genocea Biosciences (NASDAQ:GNCA)

Earnings by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Earnings History by Quarter for Genocea Biosciences (NASDAQ GNCA)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($0.41)N/AView Earnings Details
11/2/2017Q3 2017($0.51)($0.59)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.54)ViewN/AView Earnings Details
5/4/20173/31/2017($0.54)($0.48)ViewListenView Earnings Details
2/16/2017Q416($0.45)($0.56)ViewN/AView Earnings Details
11/3/2016Q316($0.44)($0.45)ViewN/AView Earnings Details
8/4/2016Q216($0.44)($0.39)ViewN/AView Earnings Details
5/5/2016Q116($0.42)($0.35)$0.24 millionViewN/AView Earnings Details
2/11/2016Q415($0.40)($0.37)$0.22 millionViewListenView Earnings Details
11/5/2015Q315($0.43)($0.37)$0.21 millionViewListenView Earnings Details
8/6/2015Q215($0.51)($0.43)$0.12 millionViewN/AView Earnings Details
5/7/2015Q115($0.57)($0.64)$0.12 millionViewListenView Earnings Details
2/12/2015Q414($0.53)($0.66)$0.31 millionViewListenView Earnings Details
11/6/2014Q314($0.43)($0.53)ViewN/AView Earnings Details
8/6/2014Q2($0.42)($0.41)ViewN/AView Earnings Details
5/6/2014Q114($0.60)($0.76)$0.26 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genocea Biosciences (NASDAQ:GNCA)
Current Year EPS Consensus Estimate: $-1.91 EPS
Next Year EPS Consensus Estimate: $-1.22 EPS

Dividends

Dividend History for Genocea Biosciences (NASDAQ:GNCA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Genocea Biosciences (NASDAQ GNCA)

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 34.05%
Insider Trades by Quarter for Genocea Biosciences (NASDAQ:GNCA)
Institutional Ownership by Quarter for Genocea Biosciences (NASDAQ:GNCA)

Insider Trades by Quarter for Genocea Biosciences (NASDAQ GNCA)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/24/2017Jonathan PooleCFOSell45,000$6.00$270,000.00View SEC Filing  
11/8/2016Eric S. HoffmanInsiderBuy7,000$3.49$24,430.00View SEC Filing  
11/7/2016Jonathan PooleCFOBuy7,000$3.34$23,380.00View SEC Filing  
11/7/2016William D. ClarkInsiderBuy2,800$3.49$9,772.00View SEC Filing  
5/9/2016Jonathan PooleCFOBuy4,000$3.88$15,520.00View SEC Filing  
12/16/2015William D ClarkCEOBuy3,800$6.45$24,510.00View SEC Filing  
9/1/2015Jessica Baker FlechtnerVPSell2,229$11.35$25,299.15View SEC Filing  
6/19/2015Polaris Venture Management Co.Major ShareholderSell30,004$13.04$391,252.16View SEC Filing  
6/17/2015Polaris Venture Management Co.Major ShareholderSell10,618$13.01$138,140.18View SEC Filing  
6/16/2015Polaris Venture Management Co.Major ShareholderSell46,000$13.24$609,040.00View SEC Filing  
6/1/2015Jessica Baker FlechtnerVPSell2,229$10.52$23,449.08View SEC Filing  
5/1/2015Jessica Baker FlechtnerVPSell2,229$10.21$22,758.09View SEC Filing  
4/1/2015Jessica Baker FlechtnerVPSell2,283$11.77$26,870.91View SEC Filing  
3/17/2015Stephen J HoffmanDirectorBuy700,000$8.25$5,775,000.00View SEC Filing  
2/2/2015Jessica Baker FlechtnerVPSell4,699$8.50$39,941.50View SEC Filing  
9/12/2014Jessica Baker FlechtnerVPSell6,435$12.00$77,220.00View SEC Filing  
9/11/2014Paul GiannascaVPSell4,071$11.84$48,200.64View SEC Filing  
9/10/2014Paul GiannascaVPSell834$12.35$10,299.90View SEC Filing  
9/9/2014Paul GiannascaVPSell2,455$12.43$30,515.65View SEC Filing  
9/8/2014Paul GiannascaVPSell2,970$12.80$38,016.00View SEC Filing  
8/29/2014Paul GiannascaVPSell6,760$12.50$84,500.00View SEC Filing  
8/14/2014Polaris Venture Management Co.Major ShareholderSell9,660$13.01$125,676.60View SEC Filing  
8/12/2014Polaris Venture Management Co.Major ShareholderSell63,794$13.28$847,184.32View SEC Filing  
2/10/2014Plc GlaxosmithklineInsiderBuy143,773$12.00$1,725,276.00View SEC Filing  
2/10/2014Polaris Venture Management Co.Major ShareholderBuy232,820$12.00$2,793,840.00View SEC Filing  
2/10/2014Stephen J HoffmanDirectorBuy250,931$12.00$3,011,172.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Genocea Biosciences (NASDAQ GNCA)

Source:
DateHeadline
Genocea Biosciences (GNCA) Presents At Stifel 2017 Healthcare Conference - SlideshowGenocea Biosciences (GNCA) Presents At Stifel 2017 Healthcare Conference - Slideshow
seekingalpha.com - November 18 at 12:43 AM
GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action ... - Business Wire (press release)GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action ... - Business Wire (press release)
www.businesswire.com - November 17 at 5:46 PM
GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 17 at 5:46 PM
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action LawsuitSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Genocea Bioscience, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - November 17 at 11:54 AM
GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class ... - GlobeNewswire (press release)
globenewswire.com - November 16 at 2:49 PM
SHAREHOLDER ALERT: Berger & Montague, P.C. Announces ... - PR Newswire (press release)SHAREHOLDER ALERT: Berger & Montague, P.C. Announces ... - PR Newswire (press release)
www.prnewswire.com - November 16 at 2:49 PM
SHAREHOLDER ALERT: Berger & Montague, P.C. Announces Investigation of Genocea Biosciences, Inc. (GNCA)SHAREHOLDER ALERT: Berger & Montague, P.C. Announces Investigation of Genocea Biosciences, Inc. (GNCA)
finance.yahoo.com - November 16 at 2:49 PM
GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Genocea Biosciences, Inc. and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 16 at 2:49 PM
Reviewing Genocea Biosciences (GNCA) & Novelion Therapeutics (NVLN)Reviewing Genocea Biosciences (GNCA) & Novelion Therapeutics (NVLN)
www.americanbankingnews.com - November 16 at 8:00 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of Commencement of a ... - Business Wire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of Commencement of a ... - Business Wire (press release)
www.businesswire.com - November 15 at 5:44 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018
finance.yahoo.com - November 15 at 5:44 AM
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit ... - GlobeNewswire (press release)EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit ... - GlobeNewswire (press release)
globenewswire.com - November 15 at 12:42 AM
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 – GNCAEQUITY ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Genocea Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2018 – GNCA
finance.yahoo.com - November 14 at 7:42 PM
IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Securities Class Action Lawsuit has been Filed on Behalf of Investors who Purchased and Suffered Losses in Genocea Biosciences, Inc.IMPORTANT GENOCEA BIOSCIENCES, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP Announces that a Securities Class Action Lawsuit has been Filed on Behalf of Investors who Purchased and Suffered Losses in Genocea Biosciences, Inc.
finance.yahoo.com - November 14 at 7:42 PM
URGENT: Monteverde & Associates PC Invites Genocea ... - PR Newswire (press release)URGENT: Monteverde & Associates PC Invites Genocea ... - PR Newswire (press release)
www.prnewswire.com - November 13 at 9:35 AM
Genocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by BrokeragesGenocea Biosciences, Inc. (GNCA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
URGENT: Monteverde & Associates PC Invites Genocea Biosciences, Inc. Shareholders with Losses in Excess of $100,000 To Contact the Firm Immediately - GNCAURGENT: Monteverde & Associates PC Invites Genocea Biosciences, Inc. Shareholders with Losses in Excess of $100,000 To Contact the Firm Immediately - GNCA
finance.yahoo.com - November 12 at 9:57 AM
Robbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Amended Class ... - Business Wire (press release)Robbins Arroyo LLP: Genocea Biosciences, Inc. (GNCA) Misled Shareholders According to a Recently Amended Class ... - Business Wire (press release)
www.businesswire.com - November 11 at 7:22 AM
INVESTOR ALERT: Kaplan Fox Announces Investigation Of ... - PR Newswire (press release)INVESTOR ALERT: Kaplan Fox Announces Investigation Of ... - PR Newswire (press release)
www.prnewswire.com - November 9 at 6:13 AM
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. (NASDAQ: GNCA) To Contact Brower Piven Before The Lead Plaintiff DeadlineSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Genocea Bioscience, Inc. (NASDAQ: GNCA) To Contact Brower Piven Before The Lead Plaintiff Deadline
finance.yahoo.com - November 9 at 6:12 AM
The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Genocea Biosciences, Inc.The Klein Law Firm Notifies Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Genocea Biosciences, Inc.
finance.yahoo.com - November 9 at 6:12 AM
GNCA INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Genocea ... - Business Wire (press release)GNCA INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Genocea ... - Business Wire (press release)
www.businesswire.com - November 8 at 8:08 AM
Genocea to Present at Stifel 2017 Healthcare Conference - GlobeNewswire (press release)Genocea to Present at Stifel 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - November 8 at 8:08 AM
Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017Genocea Presents New Data Demonstrating the Power and Versatility of its ATLAS™ Antigen Identification Platform at SITC 2017
finance.yahoo.com - November 8 at 8:08 AM
INVESTOR ALERT: Kaplan Fox Announces Investigation Of Genocea Biosciences, Inc.INVESTOR ALERT: Kaplan Fox Announces Investigation Of Genocea Biosciences, Inc.
finance.yahoo.com - November 8 at 8:08 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - GNCASHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Genocea Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline - GNCA
finance.yahoo.com - November 8 at 8:08 AM
GNCA INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Genocea Biosciences, Inc. InvestorsGNCA INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Genocea Biosciences, Inc. Investors
finance.yahoo.com - November 8 at 8:08 AM
Genocea to Present at Stifel 2017 Healthcare ConferenceGenocea to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 8:08 AM
Genocea Biosciences, Inc. (GNCA) Expected to Announce Earnings of -$0.46 Per ShareGenocea Biosciences, Inc. (GNCA) Expected to Announce Earnings of -$0.46 Per Share
www.americanbankingnews.com - November 7 at 9:34 PM
GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea ...GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea ...
www.businesswire.com - November 7 at 1:20 AM
GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.GNCA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.
finance.yahoo.com - November 7 at 1:20 AM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an ... - Business Wire (press release)INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an ... - Business Wire (press release)
www.businesswire.com - November 5 at 2:01 AM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Genocea Biosciences, Inc ... - GlobeNewswire (press release)Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Genocea Biosciences, Inc ... - GlobeNewswire (press release)
globenewswire.com - November 4 at 1:52 AM
Genocea Biosciences, Inc. (GNCA) Announces  Earnings ResultsGenocea Biosciences, Inc. (GNCA) Announces Earnings Results
www.americanbankingnews.com - November 3 at 10:46 PM
Genocea Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Genocea Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:52 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Genocea Biosciences ... - GlobeNewswire (press release)SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Genocea Biosciences ... - GlobeNewswire (press release)
globenewswire.com - November 3 at 8:52 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Genocea Biosciences, Inc. and Certain Officers – GNCASHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Genocea Biosciences, Inc. and Certain Officers – GNCA
finance.yahoo.com - November 3 at 8:52 PM
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.
finance.yahoo.com - November 3 at 8:52 PM
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Genocea Biosciences, Inc. (GNCA)Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Genocea Biosciences, Inc. (GNCA)
finance.yahoo.com - November 3 at 8:51 PM
Genocea Reports Third Quarter 2017 Financial ResultsGenocea Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 9:42 PM
Genocea Biosciences reports 3Q lossGenocea Biosciences reports 3Q loss
finance.yahoo.com - November 2 at 9:42 PM
Genocea Biosciences (GNCA) "Overweight" Rating Reiterated at Piper Jaffray CompaniesGenocea Biosciences' (GNCA) "Overweight" Rating Reiterated at Piper Jaffray Companies
www.americanbankingnews.com - November 2 at 1:16 PM
GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release)GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses ... - Business Wire (press release)
www.businesswire.com - November 1 at 9:03 PM
Scott+Scott, Attorneys at Law, LLP Files Class Action Suit Against Genocea Biosciences, Inc. (GNCA) - PR Newswire (press release)Scott+Scott, Attorneys at Law, LLP Files Class Action Suit Against Genocea Biosciences, Inc. (GNCA) - PR Newswire (press release)
www.prnewswire.com - November 1 at 9:03 PM
Scott+Scott, Attorneys at Law, LLP Files Class Action Suit Against Genocea Biosciences, Inc. (GNCA)Scott+Scott, Attorneys at Law, LLP Files Class Action Suit Against Genocea Biosciences, Inc. (GNCA)
finance.yahoo.com - November 1 at 9:03 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Genocea Bioscience, Inc. (GNCA) & Lead Plaintiff Deadline: January 2, 2018
finance.yahoo.com - November 1 at 9:03 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.
finance.yahoo.com - November 1 at 9:03 PM
GENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Genocea Biosciences, Inc. To Contact The FirmGENOCEA LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Genocea Biosciences, Inc. To Contact The Firm
finance.yahoo.com - November 1 at 9:03 PM
GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.GNCA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Genocea Biosciences, Inc.
finance.yahoo.com - November 1 at 9:03 PM
Genocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ETGenocea to Host Third Quarter 2017 Financial Results Conference Call & Webcast on November 2, 2017 at 9 a.m. ET
finance.yahoo.com - October 26 at 8:57 AM

Social Media

Financials

Chart

Genocea Biosciences (NASDAQ GNCA) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.